Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
Boris Pasche, President and CEO at Karmanos Cancer Institute, shared a post on LinkedIn:
“Karmanos Cancer Institute continues to lead in medical science by providing patients with exceptional treatment opportunities for cancer and hematologic diseases.
As a pioneer in Theranostics, phase I trials, medical devices, and now gene therapy for hemophilia, Karmanos exemplifies its mission to transform care, research, and education in these fields through courage, commitment, and compassion.
With 17 locations throughout Michigan, Karmanos also offers second opinions, often introducing patients to novel therapies they may not have previously considered.
For more information on their groundbreaking work, check out this article: Karmanos is first independent cancer center to treat hemophilia B with new gene therapy.”
Stay updated with Hemostasis Today.
-
May 8, 2026, 19:37Mostafa Faisal Mohammed Saleh: Exploring the Role of AI and Learning in Monitoring Iron Overload in Beta-Thalassemia
-
May 8, 2026, 19:27Spelile Mutupira: Hemostasis – How the Body Stops Bleeding Naturally
-
May 8, 2026, 19:15Not All TF Activity Assays Measure Tissue Factor – RPTH Journal
-
May 8, 2026, 18:48Carlos Penalillo Pimentel: Detection of Rare Blood Donor Phenotypes During Investigation of Serologic Discrepancies
-
May 8, 2026, 18:23How SCD Affects Daily Life in sub-Saharan Africa? – American Society of Hematology
-
May 8, 2026, 18:03Risk of Thrombosis After Stopping Anticoagulation in APS With aPL Negativization -JTH
-
May 8, 2026, 17:35Gurpreet Kaur Sagoo: A Rare Bone Marrow Failure Syndrome That Challenges Early Diagnosis
-
May 8, 2026, 17:31Edward Lee Carter։ Stroke Prevention Starts in the Emergency Department – but Doesn’t End There
-
May 8, 2026, 17:14Hayder Kadhim: Determinants and Outcomes of OAC Discontinuation in Atrial Fibrillation